Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy

Anti-Cancer Drugs

Volumn 12, Issue 1, 2001, Pages 1-6

  Nemoto, K ^a   Shibamoto, Y ^a   Ohmagari, J I ^a   Baba, Y ^a   Ebe, K ^a   Ariga, H ^a   Takai, Y ^a   Ouchi, A ^a   Sasai, K ^a   Shinozaki, M ^a   Tsujitani, M ^a   Sakaguchi, M ^a   Yamada, S ^a   Sakamoto, K ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Doranidazole; Hypoxic cell sensitizer; Phase I; Radiosensitizer

Indexed keywords

2 NITROIMIDAZOLE DERIVATIVE; 2 NITROIMIDAZOLE NUCLEOSIDE ANALOG; DORANIDAZOLE; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BEAM THERAPY; BLOOD TOXICITY; CANCER; CANCER RADIOTHERAPY; CELL HYPOXIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HALF LIFE TIME; HUMAN; HYPOXIC CELL; IRRADIATION; MALE; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AREA UNDER CURVE; CELL HYPOXIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEOPLASMS; RADIATION-SENSITIZING AGENTS; TREATMENT OUTCOME;

EID: 0035122495     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200101000-00001     Document Type: Article

References (23)

1. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
2. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
3. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome
4. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix
5. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer
6. Radiation, hypoxia and genetic stimulation: Implication for future therapies
7. The hypoxic cell: A target for selective cancer therapy - Eighteenth Bruce F Cain Memorial Award Lecture
8. A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: A interim report from the Medical Research Council Working Party on advancedcarcinoma of the cervix
9. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas
10. A phase I study of a hypoxic cell sensitizer KU-2285 in combination with conventional radiotherapy
11. Results of a European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas
12. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85
13. Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: Final results of RTOG 8005
14. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors
15. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: Report from the DAHANCA 2 study
16. Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): Radiosensitization efficiency and toxicity
17. In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas
18. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole
19. Evaluation of a new 2-nitroimidazole nucleoside analogue, RK-28 as a radiosensitizer for clinical use
20. Radiosensitization by a new nucleoside analogue: 1-[2-hydroxy-1-(hydroxymethyl)ethoxy]-methyl-2-nitroimidazole (RP-170)
21. The role of misonidazole combined with intraoperative radiation therapy in the treatment of pancreatic carcinoma
22. RTOG #8906: A phase I study to evaluate intraoperative radiation therapy and the hypoxic cell sensitizer etanidazole in locally advanced malignancies
23. A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy